ALINS Stock Overview
Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Intrasense S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.32 |
| 52 Week High | €0.55 |
| 52 Week Low | €0.20 |
| Beta | -0.69 |
| 1 Month Change | 16.36% |
| 3 Month Change | -3.61% |
| 1 Year Change | -26.61% |
| 3 Year Change | -68.03% |
| 5 Year Change | 26.98% |
| Change since IPO | -95.56% |
Recent News & Updates
Shareholder Returns
| ALINS | FR Healthcare Services | FR Market | |
|---|---|---|---|
| 7D | 9.2% | -1.3% | -0.03% |
| 1Y | -26.6% | -0.8% | 1.8% |
Return vs Industry: ALINS underperformed the French Healthcare Services industry which returned -1.8% over the past year.
Return vs Market: ALINS underperformed the French Market which returned 1.7% over the past year.
Price Volatility
| ALINS volatility | |
|---|---|
| ALINS Average Weekly Movement | 25.3% |
| Healthcare Services Industry Average Movement | 6.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALINS's share price has been volatile over the past 3 months.
Volatility Over Time: ALINS's weekly volatility has increased from 14% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 74 | Nicolas Reymond | www.intrasense.fr |
Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. The company offers Myrian Imaging Layer, a multimodal visualization software platform suite for health industrials; Myrian Studio, a solution for the development of medical imaging applications for innovators, industrial clients, spin-offs, and research labs; and Myrian technologies to develop biomarkers and artificial intelligence solutions. It also provides Myrian Clinical Apps, a portfolio of clinical applications for advanced post-processing, which include Myrian XP-Breast; Myrian XP-Prostate; Myrian XP-Liver; Myrian XP-Mammo; Myrian XP-Lung; Myrian XP-Colon; Myrian XL-Onco, a lesion tracking solutions; Myrian XP-Vessel; Myrian XP-Cardiac; solution for pathology or organ; and various tools for the analysis of MRI, CT, conventional, radiology, and nuclear imaging exams.
Intrasense S.A. Fundamentals Summary
| ALINS fundamental statistics | |
|---|---|
| Market cap | €16.71m |
| Earnings (TTM) | -€3.58m |
| Revenue (TTM) | €3.31m |
5.1x
P/S Ratio-4.7x
P/E RatioIs ALINS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALINS income statement (TTM) | |
|---|---|
| Revenue | €3.31m |
| Cost of Revenue | €4.19m |
| Gross Profit | -€885.00k |
| Other Expenses | €2.69m |
| Earnings | -€3.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.069 |
| Gross Margin | -26.78% |
| Net Profit Margin | -108.29% |
| Debt/Equity Ratio | 13.5% |
How did ALINS perform over the long term?
See historical performance and comparison